SINT — what changed in the latest 10-Q
A section-by-section comparison of SINT's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-08-11 vs the prior 10-Q · 2026-05-15
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +25 | −19 | ~6 | 16 |
| Controls & procedures | Text added/removed | 0 | 0 | ~2 | 2 |
| Legal proceedings | Text added/removed | +1 | −1 | 0 | 0 |
| Risk factors | No material changes reported (points to the 10-K) | — | — | — | — |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Not shown (absent or not faithfully extractable): Market risk (Item 3), Other information
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-08-11
For the three months ended June 30, 2026, total revenue increased $0.3 million, or 199%, compared to the same period in 2025. For the six months ended June 30, 2026, total revenue increased $0.3 million, or 60%, compared to the same period in 2025. When excluding the total revenue decrease of $0.1 m…
For the three months ended June 30, 2026, product revenue increased $0.3 million, or 347%, compared to the same period in 2025. For the six months ended June 30, 2026, product revenue increased $0.4 million, or 91%, compared to the same period in 2025. When excluding the product revenue decrease of …
Total revenue increased compared with the prior-year periods, primarily reflecting higher product sales from the Company’s operations. Comparability to the prior year was also affected by the divestiture of the TA&T subsidiary during the first quarter of 2025.
Product revenue growth was driven primarily by increased sales within the Company’s OEM technical manufacturing products, reflecting improved customer demand and pricing, together with initial commercial sales of the SiNAPTIC Foot & Ankle Osteotomy Wedge System. These increases were partially offset…
The Company continues to support its OEM technical manufacturing product line as an important source of revenue and cash flow. Recent pricing initiatives have improved the profitability of this product line while allowing the Company to continue investing in the commercialization of its proprietary …
Text removed vs the prior filing · source: 10-Q · 2026-05-15
For the three months ended March 31, 2026, total revenue increased $11,000, or 3%, compared to the same period in 2025. When excluding the total revenue decrease of $109,000 due to the sale of the TA&T subsidiary, the remaining total revenue increased by $120,000, or 46%.
For the three months ended March 31, 2026, product revenue increased $9,000, or 3%, compared to the same period in 2025. When excluding the product revenue decrease of $64,000 due to the sale of the TA&T subsidiary, the remaining product revenue increased by $73,000, or 32%.
Total revenue for the period was relatively consistent with the prior year, reflecting a combination of underlying growth in the Company’s continuing operations and the impact of changes to its business portfolio.
Revenue from ongoing product lines and customer activities increased compared to the prior year period, driven by growth in the Company’s spine-related product offerings and continued demand within its OEM technical manufacturing business. In addition, activity under grant and contract programs cont…
These increases were partially offset by the absence of revenue associated with the Company’s former TA&T subsidiary, which was divested in Q1 2025.
Legal proceedings
Text added vs the prior filing · source: 10-Q · 2026-08-11
From time to time, the Company may become involved in legal proceedings arising in the ordinary course of business. The Company is not currently a party to any material pending legal proceeding.
Text removed vs the prior filing · source: 10-Q · 2026-05-15
We are not aware of any pending or threatened legal proceeding against us that could have a material adverse effect on our business, operating results or financial condition. The medical device industry is characterized by frequent claims and litigation, including claims regarding patent and other i…
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice